ClinicalTrials.gg
CompletedNCT00765804Updated Aug 31, 2010

Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye

A Phase 2 interventional study of EGP-437 with EyeGate® II System and Sodium citrate buffer solution with EyeGate® II System in Dry Eye Syndrome, sponsored by Eyegate Pharmaceuticals, Inc.. Completed at 2 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2010-08-31.

Sponsored by Eyegate Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
89
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 544 studies in Dry Eye Syndromes with a site in United States — 52 open to participants now, 63 under way, 3 of them phase 3. Dry Eye Syndromes · United States.

Enrollment
199th of 473
89 · median 60
Started
2008
with 21 others
Phase 2
97 of 544
5 open now
Registered
69th of 544
by date

Among the 544 studies in Dry Eye Syndromes with a site in United States, this one is the 199th largest by enrollment of the 473 interventional ones that give a count, is one of 22 that started in 2008, is one of 97 in phase 2, and was the 69th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

52 of the 544 studies in Dry Eye Syndromes with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 544 studies in Dry Eye Syndromes with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and efficacy of iontophoretic delivery of dexamethasone phosphate ophthalmic solution using the EyeGate® II Drug Delivery System in patients with dry eye.

Read the detailed description

The objective of this study is to assess the safety and efficacy of Ocular Iontophoresis with Dexamethasone Phosphate 40 mg/mL 7.5 mA-min at 2.5 mA and Ocular Iontophoresis with Dexamethasone Phosphate 40 mg/mL 10.5 mA-min at 3.5 mA compared to placebo for the treatment of the signs and symptoms of dry eye.

03

Conditions studied

  • Dry Eye Syndrome

Browse trials for

Keywords

  • Dry Eye
  • Iontophoresis
  • Ophthalmic Delivery
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a reported history of dry eye in each eye
  • Be at least 12 years of age
  • Demonstrate a response when exposed to the Controlled Adverse Environment model

Exclusion criteria

Exclusion Criteria:

  • Have to the use of the test articles
  • Have known allergy or sensitivity to the study medication or their components (including )
  • Have any ocular infections, active ocular inflammation or preauricular lymphadenopathy
  • Be current contact lens wearers or wear contacts during the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
89 participants (actual)

Study arms

  • Active comparator
    Low Dose: DP 7.5 mA-min at 2.5 mA

    Ocular Iontophoresis with EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) 7.5 mA-min at 2.5 mA

    Drug: EGP-437 with EyeGate® II System

  • Active comparator
    High Dose: DP 10.5 mA-min at 3.5 mA

    Ocular Iontophoresis with EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) 10.5 mA-min at 3.5 mA

    Drug: EGP-437 with EyeGate® II System

  • Placebo comparator
    Placebo: 10.5 mA-min at 3.5 mA

    Ocular Iontophoresis with Placebo (sodium citrate buffer solution 100 mM at 10.5 mA-min at 3.5 mA)

    Drug: Sodium citrate buffer solution with EyeGate® II System

Interventions

  • DrugEGP-437 with EyeGate® II System

    Drug page: Dexamethasone phosphate

    Transscleral iontophoretic delivery of EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) delivered via EyeGate® II Drug Delivery System

    Also known as: Dexamethasone phosphate ophthalmic solution

  • DrugSodium citrate buffer solution with EyeGate® II System

    Transscleral iontophoretic delivery of sodium citrate buffer solution 100 mM delivered via EyeGate® II Drug Delivery System

    Also known as: Sodium citrate buffer solution

06

What researchers measure

Primary outcomes

  1. Sign: Corneal fluorescein staining after CAE exposure at Visit 5

    Corneal fluorescein staining after CAE exposure at Visit 5 as measured by the ORA scale.

    Time frame: Visit 5 (Day 7 ± 2 Days)

  2. Symptom: Ocular discomfort during CAE exposure at Visit 5

    Symptom: Ocular discomfort during CAE exposure at Visit 5 as measured by ORA scale.

    Time frame: Visit 5 (Day 7 ± 2 Days)

Secondary outcomes

  1. Sign: Fluorescein staining at each visit over 3 weeks

    Fluorescein staining (each region) as measured by the ORA and NEI Scales at each of 7 visits over 3 weeks

    Time frame: 7 visits / 3 weeks

  2. Symptom: Ocular discomfort pre and post CAE

    Symptom: Ocular discomfort pre and post CAE (ORA Scale)at 3 visits (Visits 1, 3, and 5)

    Time frame: Visit 1 (Day -7 ± 2 Days), Visit 3 (Day 0), and Visit 5 (Day 7 ± 2 Days)

07

Study locations

2 sites
  • Ophthalmic Research Associates
    Andover, Massachusetts 01810, United States
  • Ophthalmic Research Associates
    North Andover, Massachusetts 01845, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2008
First posted
Oct 3, 2008
Start
Oct 2008
Primary completionActual
Feb 2009
CompletionActual
Feb 2009
Results delay requested
Aug 20, 2010
Last update
Aug 31, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00765804
Lead sponsor
Eyegate Pharmaceuticals, Inc.
First posted
Oct 3, 2008
Start date
Oct 2008
Primary completion
Feb 2009
Completion
Feb 2009
Last update
Aug 31, 2010

Study contacts

Gail Torkildsen, MD
principal investigator · ORA, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone phosphate

Start the discussion